Study evaluating the Safety and Efficacy of Etentamig (ABBV-383) in Subjects with Light Chain Amyloidosis
M24-209
Phase 2 other active
Quick answer
Study evaluating the Safety and Efficacy of Etentamig (ABBV-383) in Subjects with Light Chain Amyloidosis for Light Chain Amyloidosis is a Phase 2 program (other) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Light Chain Amyloidosis
- Phase
- Phase 2
- Modality
- other
- Status
- active